Back to discover
Disease

Tuberculosis, Pulmonary

Late-stage therapeutic developmentEmerging research
MeSHTuberculosis, Pulmonary
2
Publications
17
Clinical trials
2
Related conditions
2023
Latest publication
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this disease.

What's happening now

An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.

Executive briefingUpdating summary…Momentum: Low
Key developments
  • 3 clinical trials expected to report results, the earliest in Q4 2026.
Upcoming Milestones
Major developments
Upcoming trial readoutImportant
Pragmatic Trial on the Safety and Tolerability of an Optimized Dose of Rifampicin in Tuberculosis Patients
Results expected Q4 20262026-01-21
Upcoming trial readoutImportant
Program for Rifampicin-Resistant Disease With Stratified Medicine for Tuberculosis (PRISM-TB)
Results expected Q3 20312026-01-20
Clinical Milestones4View
Results expected 3
Recently completed 1
Activity timeline4

Therapeutic landscape

Therapies with a regulatory footing for this condition, alongside the wider set of agents co-studied with it in the literature.

Approved & established therapies
Pretomanidapproved

Approval — Dovprela is indicated in combination with bedaquiline and linezolid, in adults, for the t… (2020)

Bedaquiline fumarateapproved

Approval —  Sirturo is indicated for use as part of an appropriate combination regimen in adult… (2014)

Delamanidapproved

Approval — Deltyba is indicated for use as part of an appropriate combination regimen for pulmonary… (2014)

Clinical trials

15 sponsors · 1 new · 0 completed in the last 12 months (net +1)

The current development programme across all trial phases.

Clinical programme
17
All trials
6
Active
13
Late-stage
6
Completed
Late-stage studies

Program for Rifampicin-Resistant Disease With Stratified Medicine for Tuberculosis (PRISM-TB)

Phase 2/3 · Recruiting · University of California, San Francisco

Phase 2C Clinical Trial of Novel, Short-course Regimens for the Treatment of Pulmonary Tuberculosis: CRUSH-TB (Combination Regimens for Shortening TB Treatment)

Phase 2/3 · Active, not recruiting · Centers for Disease Control and Prevention

Double-blind, Randomized, Placebo-controlled Trial to Evaluate the Safety and Efficacy of Atorvastatin to Reduce Inflammation After Tuberculosis Treatment Completion in HIV-infected and HIV-uninfected Adults Measured by FDG-PET/CT

Phase 2/3 · Recruiting · University of Cape Town

Pragmatic Trial on the Safety and Tolerability of an Optimized Dose of Rifampicin in Tuberculosis Patients

Phase 3 · Recruiting · Radboud University Medical Center

Evaluation of the Efficacy and Safety of a Short-course, Daily, 4-month Regimen Including Isoniazid, Pyrazinamide, Rifapentine and Moxifloxacin (2HZPM/2HPM) for the Treatment of Drug-susceptible Pulmonary Tuberculosis in Taiwan (ESCAPE-TB)

Phase 3 · Active, not recruiting · Kaohsiung Veterans General Hospital.

Repurposing a Lipid Lowering Drug to Treat Tuberculosis: Effectiveness of Statins as Adjuvant to Treatment of Pulmonary Tuberculosis in Nigeria

Phase 2/3 · Completed · Obafemi Awolowo University Teaching Hospital
Recruiting

Program for Rifampicin-Resistant Disease With Stratified Medicine for Tuberculosis (PRISM-TB)

Phase 2/3 · Recruiting · University of California, San Francisco

Double-blind, Randomized, Placebo-controlled Trial to Evaluate the Safety and Efficacy of Atorvastatin to Reduce Inflammation After Tuberculosis Treatment Completion in HIV-infected and HIV-uninfected Adults Measured by FDG-PET/CT

Phase 2/3 · Recruiting · University of Cape Town

Pragmatic Trial on the Safety and Tolerability of an Optimized Dose of Rifampicin in Tuberculosis Patients

Phase 3 · Recruiting · Radboud University Medical Center

Characterization of Tuberculosis Associated Lung Fibrosis and Respiratory Impairment, and Prevention Using Doxycycline in A Double Blind Randomized Controlled Trial

Phase 2 · Recruiting · Makerere University
Recently completed

Repurposing a Lipid Lowering Drug to Treat Tuberculosis: Effectiveness of Statins as Adjuvant to Treatment of Pulmonary Tuberculosis in Nigeria

Phase 2/3 · Completed · Obafemi Awolowo University Teaching Hospital

Two-month Regimens Using Novel Combinations to Augment Treatment Effectiveness for Drug-sensitive Tuberculosis

Phase 2/3 · Completed · University College, London

An Open-Label, Partially Randomized Trial to Evaluate the Efficacy, Safety and Tolerability of a 4-month Treatment of Bedaquiline Plus Pretomanid Plus Moxifloxacin Plus Pyrazinamide (BPaMZ) Compared to a 6-month Treatment of HRZE/HR (Control) in Adult Participants With Drug-Sensitive Smear-Positive Pulmonary Tuberculosis (DS-TB) and a 6-month Treatment of BPaMZ in Adult Participants With Drug Resistant, Smear-Positive Pulmonary Tuberculosis (DR-TB)

Phase 2/3 · Completed · Global Alliance for TB Drug Development

A Phase 3 Open-Label Partially Randomized Trial to Evaluate the Efficacy, Safety and Tolerability of the Combination of Moxifloxacin Plus PA-824 Plus Pyrazinamide After 4 and 6 Months of Treatment in Adult Subjects With Drug-Sensitive Smear-Positive Pulmonary Tuberculosis and After 6 Months of Treatment in Adult Subjects With Multi-Drug Resistant, Smear-Positive Pulmonary Tuberculosis.

Phase 3 · Completed · Global Alliance for TB Drug Development

Optimization of the TB Treatment Regimen Cascade

Phase 3 · Completed · Damien Foundation

Trial of Adjunctive Vitamin D in Tuberculosis Treatment

Phase 3 · Completed · Barts & The London NHS Trust

Regulatory timeline

Drug regulatory events matched to this condition by indication — EMA.

First approvals
2020emaApproval — Pretomanid· Dovprela is indicated in combination with bedaquiline and linezolid, in adults, for the treatment of pulmonary extensively drug resistant (XDR), or treatment-intolerant or nonresponsive multidrug-resistant (MDR) tuberculosis (TB). Consideration should be given to official guidance on the appropriate use of antibacterial agents. source ↗
2014emaApproval — Delamanid· Deltyba is indicated for use as part of an appropriate combination regimen for pulmonary multi-drug resistant tuberculosis (MDR-TB) in adults, adolescents, children and infants with a body weight of at least 10 kg when an effective treatment regimen cannot otherwise be composed for reasons of resistance or tolerability (see sections 4.2, 4.4 and 5.1). Consideration should be given to official guidance on the appropriate use of antibacterial agents. source ↗
2014emaApproval — Bedaquiline fumarate·  Sirturo is indicated for use as part of an appropriate combination regimen in adult and paediatric patients (2 years to less than 18 years of age and weighing at least 7 kg) with pulmonary tuberculosis (TB) due to Mycobacterium tuberculosis resistant to at least rifampicin and isoniazid. Consideration should be given to official guidance on the appropriate use of antibacterial agents.   source ↗

European Medicines Agency (CC BY 4.0). Events are matched to this condition by drug indication text — approvals/updates for drugs indicated for it, not disease-specific acts.

Research activity

2 papers

Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.

Publications over time
20172023
Major themes5
  • Interleukin-271
  • Latent Tuberculosis1
  • Mycobacterium tuberculosis1
  • Tuberculosis1
  • Tuberculosis, Pulmonary1
Leading journals2
  • Clinical infectious diseases : an official publication of the Infectious Diseases Society of America1
  • Scientific reports1
Leading researchers8
  • Cohn DL1
  • Daley CL1
  • Desmond E1
  • Eugenin E1
  • Kazmi SU1
  • Keane J1
  • Khanani R1
  • Leonard MK1
Affiliations (unnormalised)6
  • Aga Khan University Hospital1
  • Centers for Disease Control and Prevention1
  • Dadabhoy Institute of Higher Education1
  • Dow University of Health Sciences1
  • Emory University School of Medicine and.1
  • Foundation for Innovative New Diagnostics1

Related conditions

2 matches

Diseases frequently studied alongside this one. Number shows shared papers.

Latent Tuberculosis2Tuberculosis2

Reference

Authoritative identity, definition & identifiers.

Defined in MeSH

MYCOBACTERIUM infections of the lung.

Identifiers
MeSHTuberculosis, Pulmonary
References & data sources
  • Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
  • Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
  • Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
  • Related entities are derived from literature co-mention (studied together) — associative, not causal.